ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Short Interest Up 74.3% in August

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) saw a large growth in short interest during the month of August. As of August 14th, there was short interest totaling 78,401 shares, a growth of 74.3% from the July 30th total of 44,970 shares. Approximately 2.5% of the shares of the stock are sold short. Based on an average daily volume of 37,830 shares, the short-interest ratio is presently 2.1 days.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SBIO. Bank of America Corp DE boosted its stake in shares of ALPS Medical Breakthroughs ETF by 63.1% during the 1st quarter. Bank of America Corp DE now owns 98,679 shares of the company’s stock worth $5,165,000 after acquiring an additional 38,193 shares in the last quarter. LPL Financial LLC lifted its holdings in shares of ALPS Medical Breakthroughs ETF by 438.7% during the fourth quarter. LPL Financial LLC now owns 42,755 shares of the company’s stock valued at $2,190,000 after purchasing an additional 34,819 shares during the last quarter. Jones Financial Companies Lllp purchased a new stake in shares of ALPS Medical Breakthroughs ETF during the first quarter valued at $782,000. Stifel Financial Corp acquired a new position in shares of ALPS Medical Breakthroughs ETF in the 4th quarter valued at $1,018,000. Finally, Virtu Financial LLC acquired a new position in shares of ALPS Medical Breakthroughs ETF in the 3rd quarter valued at $650,000.

ALPS Medical Breakthroughs ETF Stock Down 0.3%

Shares of NYSEARCA SBIO traded down $0.17 during midday trading on Tuesday, reaching $66.65. The company’s stock had a trading volume of 30,579 shares, compared to its average volume of 37,817. ALPS Medical Breakthroughs ETF has a one year low of $34.88 and a one year high of $70.85. The company has a 50 day moving average price of $65.86 and a 200 day moving average price of $57.27.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.